Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians.
Dhar
Gauranga Chandra
GC
Bangladesh Institute of Family Medicine and Research at the University of Science and Technology of Chittagong in Dhaka, Bangladesh.
D001786:Blood Glucose / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D016903:Drug Monitoring; D005194:Family Practice / Q000592:standards; D006442:Glycated Hemoglobin / Q000187:drug effects*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents
N Engl J Med. 1993 Sep 30;329(14):977-86
8366922
Lancet. 1998 Sep 12;352(9131):837-53
9742976
N Engl J Med. 2008 Jun 12;358(24):2545-59
18539917
N Engl J Med. 2009 Jan 8;360(2):129-39
19092145
N Engl J Med. 2008 Jun 12;358(24):2537-9
18539915
N Engl J Med. 2008 Jun 12;358(24):2560-72
18539916